Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd

Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd

sales@dingminpharma.com

86-311-67591193

Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd
HomeProductsAPIs And IntermediatesAPIs Powder99.0%, Ivacaftor Powder/ VX-770, Cas:873054-44-5

99.0%, Ivacaftor Powder/ VX-770, Cas:873054-44-5

  • $5
    ≥1
    Bag/Bags
Payment Type:
L/C,T/T,Paypal
Min. Order:
1 Bag/Bags
Transportation:
Ocean,Air
Port:
Shanghai
Share:
  • Product Description
Overview
Product Attributes

Model No.873054-44-5

BrandDM

Grade StandardMedicine Grade

TypeChemical Reagent

StateSolid

VolatileNot Volatile

Supply Ability & Additional Information

Packagingdouble PE with aluminium foil bag

Productivity100kg/month

TransportationOcean,Air

Place of OriginHebei,China

Supply Ability100kg/month

CertificateISO9001

PortShanghai

Payment TypeL/C,T/T,Paypal

Packaging & Delivery
Selling Units:
Bag/Bags
Package Type:
double PE with aluminium foil bag
Picture Example:

 Product Description

 
Item Name Ivacaftor 
CAS NO 873054-44-5 
Apparence White Powder
Package Aluminum Bag;Drums;Paper Box Outside
Shipment FedEx;DHL;UPS;TNT;EMS;Sea;Air.
Payment Western Union;T/T;Trade Assurance;L/C
Warranty 2 Years

 

   Certification of Analysis

Item

Specification 

Specific rotation

+39.5 to +41.5° 

State of solution(transmittance)

Clear 98.0% min.

Chloride[cl]

0.020% max. 

Ammonium [NH4]

0.02% max. 

Sulfate[SO4]

0.020% max

Iron[Fe]

10ppm max.

Heavy metals [Pb]

10ppm max

Arsenic[As2O3]

1ppm max

Other amino acids

Chromatographically not detectable

Loss on drying

0.20% max. 

Residue on ignition[sulfated]

0.10% max.

Assay

99.0% min

 

 

 

Function&Application

Ivacaftor is a new therapeutic agent that acts at the cystic fibrosis transmembrane conductance regulator (CFTR) channel to alter activity. It is approved for use in patients 6 years and older with cystic fibrosis who have at least 1 G551D mutation in the CFTR gene. It is unlike any other current pharmacologic agent for cystic fibrosis in that it specifically targets the gene defect associated with cystic fibrosis as opposed to treating resulting symptomology. Mucoactive agents, Antibiotics, inhaled beta agonists, and other anti-inflammatory agents are currently the mainstay of cystic fibrosis treatment but can be associated with several side effects in addition to cumbersome frequency of administration. Ivacaftor's oral dosing regimen offers a more convenient treatment option.

 

Product Categories : APIs And Intermediates > APIs Powder

Email to this supplier
  • *Subject:
  • *To:
    Ms. Lily
  • *Email:
  • *Message:
    Your message must be between 20-8000 characters
HomeProductsAPIs And IntermediatesAPIs Powder99.0%, Ivacaftor Powder/ VX-770, Cas:873054-44-5
Send Inquiry
*
*

Related Products List

Home

Product

Phone

About Us

Inquiry

We will contact you immediately

Fill in more information so that we can get in touch with you faster

Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.

Send